BR112021018236A2 - Bioconjugado de um polissacarídeo de antígeno o4 glicosilado de e. coli covalentemente ligado a uma proteína transportadora, composição, métodos para induzir anticorpos, para vacinar um indivíduo e para produzir um bioconjugado, e, célula hospedeira procariótica recombinante - Google Patents
Bioconjugado de um polissacarídeo de antígeno o4 glicosilado de e. coli covalentemente ligado a uma proteína transportadora, composição, métodos para induzir anticorpos, para vacinar um indivíduo e para produzir um bioconjugado, e, célula hospedeira procariótica recombinanteInfo
- Publication number
- BR112021018236A2 BR112021018236A2 BR112021018236A BR112021018236A BR112021018236A2 BR 112021018236 A2 BR112021018236 A2 BR 112021018236A2 BR 112021018236 A BR112021018236 A BR 112021018236A BR 112021018236 A BR112021018236 A BR 112021018236A BR 112021018236 A2 BR112021018236 A2 BR 112021018236A2
- Authority
- BR
- Brazil
- Prior art keywords
- bioconjugate
- coli
- glycosylated
- producing
- methods
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 150000004676 glycans Chemical class 0.000 title abstract 6
- 229920001282 polysaccharide Polymers 0.000 title abstract 6
- 239000005017 polysaccharide Substances 0.000 title abstract 6
- 102000014914 Carrier Proteins Human genes 0.000 title abstract 3
- 108010078791 Carrier Proteins Proteins 0.000 title abstract 3
- 241000588724 Escherichia coli Species 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000051366 Glycosyltransferases Human genes 0.000 abstract 1
- 108700023372 Glycosyltransferases Proteins 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
bioconjugado de um polissacarídeo de antígeno o4 glicosilado de e. coli covalentemente ligado a uma proteína transportadora, composição, métodos para induzir anticorpos, para vacinar um indivíduo e para produzir um bioconjugado, e, célula hospedeira procariótica recombinante. são fornecidos um bioconjugado de um polissacarídeo de antígeno o4 glicosilado de e. coli covalentemente ligado a uma proteína transportadora e composições do mesmo. também são fornecidas células hospedeiras recombinantes para produzir o bioconjugado e métodos para produzir o bioconjugado usando as células hospedeiras recombinantes. as células hospedeiras recombinantes contêm um ácido nucleico que codifica uma glicosiltransferase capaz de modificar o antígeno o4 de e. coli com ramificação de glicose para produzir o polissacarídeo do antígeno o4 glicosilado. bioconjugados de um polissacarídeo de antígeno o4 glicosilado de e. coli descrito neste documento, podem ser usados sozinhos ou em combinação com um ou mais polissacarídeos de antígeno o de e. coli adicionais para induzir anticorpos contra um antígeno glicosilado de e. coli e para vacinar um indivíduo contra e. coli patogênica intestinal (expec).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962819746P | 2019-03-18 | 2019-03-18 | |
PCT/US2020/023404 WO2020191082A1 (en) | 2019-03-18 | 2020-03-18 | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021018236A2 true BR112021018236A2 (pt) | 2021-11-23 |
Family
ID=70285927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021018236A BR112021018236A2 (pt) | 2019-03-18 | 2020-03-18 | Bioconjugado de um polissacarídeo de antígeno o4 glicosilado de e. coli covalentemente ligado a uma proteína transportadora, composição, métodos para induzir anticorpos, para vacinar um indivíduo e para produzir um bioconjugado, e, célula hospedeira procariótica recombinante |
Country Status (23)
Country | Link |
---|---|
US (2) | US11446370B2 (pt) |
EP (1) | EP3941516A1 (pt) |
JP (1) | JP7370391B2 (pt) |
KR (1) | KR102532707B1 (pt) |
CN (1) | CN113924112A (pt) |
AR (1) | AR118388A1 (pt) |
AU (1) | AU2020240072A1 (pt) |
BR (1) | BR112021018236A2 (pt) |
CA (1) | CA3134216A1 (pt) |
CL (1) | CL2021002426A1 (pt) |
CO (1) | CO2021013823A2 (pt) |
CR (1) | CR20210522A (pt) |
EA (1) | EA202192390A1 (pt) |
IL (1) | IL286394A (pt) |
JO (1) | JOP20210256A1 (pt) |
MA (1) | MA55364A (pt) |
MX (1) | MX2021011445A (pt) |
PE (1) | PE20212265A1 (pt) |
SA (1) | SA521430310B1 (pt) |
SG (1) | SG11202110301TA (pt) |
TW (1) | TWI751513B (pt) |
UY (1) | UY38616A (pt) |
WO (1) | WO2020191082A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2669420T3 (es) | 2013-01-17 | 2018-05-25 | Arsanis Biosciences Gmbh | Anticuerpo específico de E.coli MDR |
MX2016011055A (es) | 2014-02-24 | 2017-10-24 | Glycovaxyn Ag | Nuevo polisacarido y usos del mismo. |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
WO2020191082A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
AR118389A1 (es) | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización |
EP4213870A1 (en) * | 2020-09-17 | 2023-07-26 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
WO2022113048A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceuticals, Inc. | Analytical method for glycoconjugates using a capillary-based immunoassay system |
TW202304504A (zh) | 2021-04-01 | 2023-02-01 | 美商詹森藥物公司 | 大腸桿菌o18生物軛合物之生產 |
KR20240005684A (ko) | 2021-04-08 | 2024-01-12 | 얀센 파마슈티칼즈, 인코포레이티드 | 바이오컨쥬게이트 생산 방법 |
CN116003531B (zh) * | 2022-12-28 | 2023-09-05 | 山东省农业科学院畜牧兽医研究所 | 噬菌体受体结合蛋白po86在大肠杆菌o抗原血清型分型鉴定中的应用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
CN1326564C (zh) | 1997-04-01 | 2007-07-18 | 科里克萨有限公司 | 单磷酰基脂质a的水性免疫佐剂组合物 |
US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
PT1126876E (pt) | 1998-10-16 | 2007-04-30 | Glaxosmithkline Biolog Sa | Sistemas adjuvantes e vacinas |
DE60134499D1 (de) | 2000-04-13 | 2008-07-31 | Corixa Corp | Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten |
AU2001253568A1 (en) | 2000-04-18 | 2001-10-30 | Dan C. Deborde | Lipopolysaccharide-conjugate vaccine for sepsis treatment |
RU2189253C1 (ru) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения |
US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
KR20090110951A (ko) | 2002-03-07 | 2009-10-23 | 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 | 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계 |
AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
CA2561577A1 (en) | 2004-03-30 | 2005-10-13 | Nsgene A/S | Therapeutic use of a growth factor, nsg33 |
EP2853600B1 (en) | 2005-05-11 | 2018-09-19 | ETH Zürich | Recombinant N-glycosylated proteins from procaryotic cells |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
JP4791866B2 (ja) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | 下痢原性大腸菌感染症の判別に用いられる固相等 |
US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
WO2009104074A2 (en) | 2008-02-20 | 2009-08-27 | Glycovaxyn Ag | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
KR101785120B1 (ko) | 2009-04-27 | 2017-10-12 | 이뮤론 리미티드 | 병적 장애의 치료 및/또는 예방에 이용되는 항-lps 풍부한 면역글로블린 조제물 |
TWI494125B (zh) | 2009-06-05 | 2015-08-01 | Infectious Disease Res Inst | 合成的葡萄吡喃糖基脂質佐劑 |
HUE038456T2 (hu) | 2009-11-19 | 2018-10-29 | Glaxosmithkline Biologicals Sa | Bioszintetikus rendszer, amely immunogén poliszaccharidokat termel prokarióta sejtekben |
CN105734678B (zh) | 2010-07-16 | 2019-11-05 | 阿迪马布有限责任公司 | 合成多核苷酸文库 |
AR084158A1 (es) | 2010-12-10 | 2013-04-24 | Merck Sharp & Dohme | Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas |
JP2014526449A (ja) | 2011-09-06 | 2014-10-06 | グリコヴァキシン アーゲー | 原核細胞において製造されるバイオコンジュゲートワクチン |
US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
JP2015529214A (ja) | 2012-09-10 | 2015-10-05 | グリコヴァキシン アーゲー | 修飾された抗原を含むバイオコンジュゲート及びその使用 |
EA201590488A1 (ru) | 2012-10-12 | 2015-09-30 | Гликоваксин Аг | Способы модификации клеток-хозяев |
ES2750525T3 (es) | 2012-12-27 | 2020-03-26 | Glaxosmithkline Biologicals Sa | Procedimientos y composiciones relacionados con CRM197 |
ES2669420T3 (es) | 2013-01-17 | 2018-05-25 | Arsanis Biosciences Gmbh | Anticuerpo específico de E.coli MDR |
PL2996473T3 (pl) | 2013-05-18 | 2020-06-01 | Aduro Biotech, Inc. | Kompozycje i sposoby aktywacji sygnałowania zależnego od „stymulatora genu interferonu” |
EP3055416B1 (en) | 2013-10-11 | 2020-01-22 | GlaxoSmithKline Biologicals S.A. | Methods of host cell modification |
AU2014359277B2 (en) | 2013-12-04 | 2017-10-26 | Glaxosmithkline Biologicals S.A. | Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli |
MX2016008794A (es) | 2014-02-06 | 2016-10-13 | Arsanis Biosciences Gmbh | Secuencias de anticuerpos especificos para e. coli. |
MX2016011055A (es) | 2014-02-24 | 2017-10-24 | Glycovaxyn Ag | Nuevo polisacarido y usos del mismo. |
ES2939470T3 (es) | 2014-04-17 | 2023-04-24 | Glaxosmithkline Biologicals Sa | Células hospedadoras modificadas y usos de las mismas |
CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
WO2016107819A1 (en) | 2014-12-30 | 2016-07-07 | Glycovaxyn Ag | Compositions and methods for protein glycosylation |
TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
WO2020191082A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
AR118389A1 (es) | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización |
FR3098334B1 (fr) | 2019-07-05 | 2021-07-23 | Airbus Operations Sas | Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef |
EP4213870A1 (en) | 2020-09-17 | 2023-07-26 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
-
2020
- 2020-03-18 WO PCT/US2020/023404 patent/WO2020191082A1/en active Application Filing
- 2020-03-18 CA CA3134216A patent/CA3134216A1/en active Pending
- 2020-03-18 TW TW109109075A patent/TWI751513B/zh active
- 2020-03-18 CN CN202080037067.6A patent/CN113924112A/zh active Pending
- 2020-03-18 JP JP2021556247A patent/JP7370391B2/ja active Active
- 2020-03-18 MA MA055364A patent/MA55364A/fr unknown
- 2020-03-18 EA EA202192390A patent/EA202192390A1/ru unknown
- 2020-03-18 SG SG11202110301TA patent/SG11202110301TA/en unknown
- 2020-03-18 EP EP20718989.5A patent/EP3941516A1/en active Pending
- 2020-03-18 PE PE2021001476A patent/PE20212265A1/es unknown
- 2020-03-18 MX MX2021011445A patent/MX2021011445A/es unknown
- 2020-03-18 AU AU2020240072A patent/AU2020240072A1/en active Pending
- 2020-03-18 UY UY0001038616A patent/UY38616A/es unknown
- 2020-03-18 JO JOP/2021/0256A patent/JOP20210256A1/ar unknown
- 2020-03-18 BR BR112021018236A patent/BR112021018236A2/pt unknown
- 2020-03-18 CR CR20210522A patent/CR20210522A/es unknown
- 2020-03-18 US US16/822,340 patent/US11446370B2/en active Active
- 2020-03-18 KR KR1020217033424A patent/KR102532707B1/ko active IP Right Grant
- 2020-03-18 AR ARP200100746A patent/AR118388A1/es unknown
-
2021
- 2021-09-14 IL IL286394A patent/IL286394A/en unknown
- 2021-09-16 CL CL2021002426A patent/CL2021002426A1/es unknown
- 2021-09-16 SA SA521430310A patent/SA521430310B1/ar unknown
- 2021-10-14 CO CONC2021/0013823A patent/CO2021013823A2/es unknown
-
2022
- 2022-07-28 US US17/815,705 patent/US11931405B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20200316184A1 (en) | 2020-10-08 |
PE20212265A1 (es) | 2021-11-30 |
TWI751513B (zh) | 2022-01-01 |
IL286394A (en) | 2021-10-31 |
AR118388A1 (es) | 2021-09-29 |
MX2021011445A (es) | 2021-10-13 |
US20230118878A1 (en) | 2023-04-20 |
TW202102255A (zh) | 2021-01-16 |
SA521430310B1 (ar) | 2023-12-13 |
KR20210141586A (ko) | 2021-11-23 |
US11931405B2 (en) | 2024-03-19 |
JP2022533883A (ja) | 2022-07-27 |
CR20210522A (es) | 2021-12-17 |
CA3134216A1 (en) | 2020-09-24 |
KR102532707B1 (ko) | 2023-05-12 |
WO2020191082A1 (en) | 2020-09-24 |
CL2021002426A1 (es) | 2022-04-29 |
WO2020191082A9 (en) | 2020-11-05 |
CN113924112A (zh) | 2022-01-11 |
US11446370B2 (en) | 2022-09-20 |
MA55364A (fr) | 2022-01-26 |
UY38616A (es) | 2020-09-30 |
CO2021013823A2 (es) | 2022-03-29 |
AU2020240072A1 (en) | 2021-10-28 |
EA202192390A1 (ru) | 2021-12-03 |
SG11202110301TA (en) | 2021-10-28 |
JOP20210256A1 (ar) | 2023-01-30 |
JP7370391B2 (ja) | 2023-10-27 |
EP3941516A1 (en) | 2022-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021018236A2 (pt) | Bioconjugado de um polissacarídeo de antígeno o4 glicosilado de e. coli covalentemente ligado a uma proteína transportadora, composição, métodos para induzir anticorpos, para vacinar um indivíduo e para produzir um bioconjugado, e, célula hospedeira procariótica recombinante | |
BR112021018258A2 (pt) | Método e célula hospedeira recombinante para preparar um bioconjugado, bioconjugado, e, composição | |
BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
BR112022023554A2 (pt) | Composições e métodos de rna circular | |
EA201691478A1 (ru) | Новый полисахарид и его применения | |
PH12020551907A1 (en) | Antagonizing cd73 antibody | |
BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
BR112018075688A2 (pt) | anticorpos anti-c5 e métodos de uso | |
BR112018009067A8 (pt) | anticorpos anti-c5 e métodos de uso | |
BR112021025130A2 (pt) | Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos | |
BR112016023688A2 (pt) | célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada | |
BRPI0314373B8 (pt) | produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico | |
BR112022000371A2 (pt) | Anticorpos claudin18 e métodos de tratamento contra câncer | |
BRPI0413314A (pt) | antìgeno quimérico para provocar uma resposta imune, métodos para realçar a apresentação de antìgeno em uma célula que apresenta antìgeno, para ativar uma célula que apresenta antìgeno, para provocar uma resposta imune, para quebrar a toleráncia, e para tratar uma condição imuno-tratável, composição farmacêutica, artigo de fabricação, método para produzir um antìgeno quimérico, polinucleotìdeo, microorganismo ou linhagem celular, e, vetor | |
BRPI0820177B8 (pt) | métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas | |
BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
MX2023007282A (es) | Moleculas de union al antigeno especificas para la variante ror1. | |
BR112022001359A2 (pt) | Método e composição para anticorpos anti-cd73 e variantes | |
BR112021019701A2 (pt) | Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos | |
MX2021000421A (es) | Métodos y composiciones que usan células dendríticas recombinantes para el tratamiento del cáncer. | |
BR112021017860A2 (pt) | Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica | |
MX2023003169A (es) | Composiciones de vacunas multivalentes y usos de las mismas. | |
BR112021024997A2 (pt) | Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso | |
ATE473762T1 (de) | Ein impfstoff | |
BR112018068865A2 (pt) | plataforma e vacinas de antígeno de fusão multiepítopo de ponta de adesina e seu uso no tratamento de diarreia enterotoxigênica |